Page 26
Figure 21 : Nature of CDx deals , 2015
Marketed , 6 % Other , 1 % Filed , 2 %
Phase III , 8 %
Phase II , 7 %
Discovery , 47 %
Phase I , 10 %
Preclinical , 20 %
Source : Patel et al ., 2015
Table 14 : Selected CDx financing rounds
Source : goetzpartners Research , Mergermarket
Liquid-based multi-parameter tests could open the door to immune profiling and targeted immunotherapies
Increased use of multi-parameter assays Until recently , CDx have focussed largely on single molecular parameters . In the case of solid tumours , the samples undergoing analysis were generally drawn from tissue removed by biopsy . The development of liquid biopsies should facilitate the increased use of multi-parameter assays . New technologies including NGS , multiplex PCR and direct detection , coupled with the inherent complexity of cancer and particularly the growth of immuno-oncology , have been driving a shift towards multi-parameter molecular assays performed in samples taken from blood . Nanostring , for example , has developed a fluorescent direct detection platform that can detect large numbers of specific genetic sequences as well as proteins simultaneously from a single sample . These multi-parameter assays aim to provide predictions of the overall prognosis , providing a “ cancer Immunogram ”.
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .